Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

Antzeko izenburuak

• Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
  nork: Maximilian Merz, et al.
  Argitaratua: (2018-01-01)
• Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
  nork: Niels Weinhold, et al.
  Argitaratua: (2016-03-01)
• Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
  nork: Maximilian Merz, et al.
  Argitaratua: (2016-12-01)
• Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
  nork: Kai Neben, et al.
  Argitaratua: (2010-07-01)
• Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
  nork: Maximilian Merz, et al.
  Argitaratua: (2015-07-01)